On June 10, 2021 Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, reported that it will be attending BIO Digital 2021, a key international biotech partnering event held virtually on June 14-18 (Press release, Notable Labs, JUN 10, 2021, View Source [SID1234583857]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, Notable will be seeking partnering opportunities to partner on and in-license investigational treatments for hematological cancers. Notable’s focus is to achieve and accelerate their development by targeting patient populations who will respond based on its prediction technology platform.

Dr. Thomas Bock, CEO of Notable said, "This conference comes at a pivotal time to expand our collaboration with current and prospective partners and leverage the recent progress we achieved for our prediction platform capabilities." Matt De Silva, Founder and Executive Chairman of the board added, "In the past months we have advanced and grown extremely fast, propelling our insights across drug classes and diseases. We are thrilled to share that excitement with potential new collaborators."

The BIO Digital conference provides access to almost 3,000 U.S. and international life science companies. The virtual gathering of the global biotech industry provides access to key partners via BIO’s One-on-One Partnering, critical education including policy, industry trends, breakthrough therapies, and patient access.

On June 10, 2021 Dr. Michael Spring, Frederic Chabot, Dr. Barry Duplantis, and Timothy Miller of ImmunoPrecise reported that it will be attending BIO Digital June10-11 & June 14-18, 2021 (Press release, ImmunoPrecise Antibodies, JUN 10, 2021, View Source [SID1234583878]). The event will host multiple speakers and one-on-one partnering meetings. BIO Digital will discuss how the biotech space has been changed by COVID, and we will take the opportunity to meet with potential partners about our COVID, and other Talem Therapeutic Assets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 10, 2021 Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, reported it has initiated patient enrollment and screening in its Phase 1 imaging study evaluating VMT01 for the treatment of metastatic melanoma (Press release, Viewpoint Molecular Targeting, JUN 10, 2021, https://viewpointmt.com/viewpoint-molecular-targeting-commences-patient-enrollment-in-phase-1-imaging-study-for-vmt01-program-for-metastatic-melanoma/ [SID1234585490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Melanoma is a cancer of the skin and the most aggressive form of skin cancer. While a disease that is identified early (when confined to the outer layers of the skin) can be cured by surgery, melanoma that migrates to distant sites in the body (metastatic melanoma) is difficult to treat. Despite the introduction of new treatments for metastatic melanoma, according to the American Cancer Society, the five-year survival is approximately 25%.

"The start of the VMT01 imaging study represents a significant milestone for the Company. The study tests Viewpoint’s investigational imaging agents in subjects with advanced melanoma to accelerate therapeutic drug development and enable image-guided treatment. We are pleased to be working alongside Mayo Clinic to advance this novel theranostic approach to radiopharmaceutical therapy against metastatic melanoma," commented Frances L. Johnson, MD, Chief Executive Officer and Co-Founder of Viewpoint Molecular Targeting. "Based on the extremely encouraging preclinical data seen to date, we believe that our targeted alpha-particle therapies have the potential to significantly enhance treatment responses in metastatic melanoma."

The Phase 1 first-in-human, crossover design study of Positron Emission Tomography (PET) and Single-Photon Emission Computerized Tomography (SPECT) scanning will enroll approximately 10 subjects with Stage III/IV unresectable melanoma. The primary endpoint of the study is safety and biodistribution. Secondary endpoints of the study are molecular target validation and image quality. The current VMT01 Phase 1 imaging study is being conducted at Mayo Clinic in Rochester, MN, and a future therapy study is planned. Provisional results for the imaging study are targeted for Q4 2021. Following the results of the imaging trial, the Company plans to initiate a multisite Phase 1/2a therapy study of VMT01 for the treatment of metastatic melanoma.

Viewpoint’s VMT01 program is intended to address an unmet clinical need with the use of a new imaging agent to guide Viewpoint’s radiopharmaceutical therapy against metastatic melanoma. This image-guided approach is often referred to as "theranostics." Using information guided by the low-risk medical imaging scan, a treatment plan utilizing the VMT01 ligand is designed to deliver the power of alpha-particle radiation specifically to melanoma tumors, while minimizing risk to unaffected organs and tissues. VMT01 represents a unique way to treat metastatic melanoma that has been vetted as scientifically sound by rigorous peer review and has the potential to be transformative for melanoma patients.

On June 10, 2021 Bristol Myers Squibb (NYSE:BMY) reported that it will announce results for the second quarter of 2021 on Wednesday, July 28, 2021 (Press release, Bristol-Myers Squibb, JUN 10, 2021, View Source [SID1234583802]). During a conference call at 8 a.m. ET on July 28, 2021, company executives will review financial results and address inquiries from investors and analysts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the call at View Source or by using this link which becomes active 15 minutes prior to the scheduled start time and entering your information to be connected. Investors and the general public can also access the live webcast by dialing in the U.S. toll free 888-204-4368 or international +1 313-209-4906, confirmation code: 1720109. Materials related to the call will be available at the same website prior to the conference call.

A replay of the call will be available beginning at 11:30 a.m. ET on July 28 through 11:30 a.m. ET on August 11, 2021. The replay will also be available through View Source or by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 1720109.

On June 10, 2021 Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, reported financial results for the quarter ended March 31, 2021 (Press release, Werewolf Therapeutics, JUN 10, 2021, View Source [SID1234583820]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our recently completed IPO will help us advance our two lead programs to the clinic and will enable us to continue to build our immuno-oncology R&D organization," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. "Despite important recent advances in the treatment of cancer, using the body’s immune system without eliciting off-target side effects remains a challenge. We are leveraging our novel PREDATOR platform to engineer conditionally activated proinflammatory immunomodulators, or INDUKINE molecules, which are delivered systemically but activated only in the tumor microenvironment, with the goal of generating potent anti-tumor response while minimizing toxicities."

Successful Initial Public Offering Completed: On May 4, 2021, Werewolf completed its initial public offering (IPO). In connection with the offering, the Company issued and sold 7,500,000 shares of common stock at a public offering price of $16.00 per share, resulting in net proceeds of approximately $108.9 million.

First Quarter 2021 Financial Highlights

Cash position: As of March 31, 2021, cash and cash equivalents decreased to $84.6 million, compared to $92.6 million as of December 31, 2020. The Company expects that its existing cash and cash equivalents, together with the net proceeds from the IPO, will be sufficient to fund its operations for at least the next twenty-four months.
Research and development expenses: Research and development expenses were $4.8 million for the first quarter of 2021, compared to $2.8 million for the same period in 2020. The increase in research and development expenses was primarily due to manufacturing expenses incurred to support the production of preclinical and future clinical trial materials associated with the Company’s product candidates WTX-124, WTX-330 and WTX-613 and increased employee compensation costs related to increased headcount.
General and administrative expenses: General and administrative expenses were $2.6 million for the first quarter of 2021, compared to $1.1 million for the same period in 2020. The increase in general and administrative expenses was primarily due to increased personnel, consulting and recruiting costs in preparation for increased requirements of operating as a public company.
Net loss: Net loss was $7.4 million for the first quarter of 2021, compared to $3.8 million for the same period in 2020.